ERAMET 
● The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
● From a short-term investment perspective, the company presents a deteriorated fundamental situation
● The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
● Its low valuation, with P/E ratio at 10.05 and 4.93 for the ongoing fiscal year and 2022 respectively, makes the stock pretty attractive with regard to earnings multiples.
● The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
● Over the last twelve months, the sales forecast has been frequently revised upwards.
● Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
● For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● Over the past four months, analysts' average price target has been revised upwards significantly.
● Analyst opinion has improved significantly over the past four months.
● Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
● According to forecast, a sluggish sales growth is expected for the next fiscal years.
● The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
● The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
● For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
● Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
● The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
